Show simple item record

dc.contributor.authorBedoya, Luis M 
dc.contributor.authorBeltran, Manuela 
dc.contributor.authorObregon-Calderon, Patricia 
dc.contributor.authorGarcía-Pérez, Javier 
dc.contributor.authorde la Torre-Tarazona, Humberto Erick 
dc.contributor.authorGonzalez-Fernandez, Nuria 
dc.contributor.authorPerez-Olmeda, Mayte 
dc.contributor.authorAuñón, David
dc.contributor.authorCapa, Laura 
dc.contributor.authorGómez-Acebo, Eduardo
dc.contributor.authorAlcamí, José 
dc.date.accessioned2020-06-02T07:31:55Z
dc.date.available2020-06-02T07:31:55Z
dc.date.issued2016
dc.identifier.citationAIDS. 2016 Nov 28;30(18):2767-2776.es_ES
dc.identifier.issn0269-9370es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/10247
dc.description.abstractOBJECTIVE: To investigate the toxicity and activity against HIV of 5-hydroxytyrosol as a potential microbicide. DESIGN: The anti-HIV-1 activity of 5-hydroxytyrosol, a polyphenolic compound, was tested against wild-type HIV-1 and viral clones resistant to nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors and integrase inhibitors. In addition to its activity against founder viruses, different viral subtypes and potential synergy with tenofovir disoproxil fumarate, lamivudine and emtricitabine was also tested. 5-Hydroxytyrosol toxicity was evaluated in vivo in rabbit vaginal mucosa. METHODS: We have cloned pol gene from drug-resistant HIV-1 isolated from infected patients and env gene from Fiebeg III/IV patients or A, C, D, E, F and G subtypes in the NL4.3-Ren backbone. 5-Hydroxytyrosol anti-HIV-1 activity was evaluated in infections of MT-2, U87-CCR5 or peripheral blood mononuclear cells preactivated with phytohemagglutinin + interleukin-2 with viruses obtained through 293T transfections. Inhibitory concentration 50% and cytotoxic concentration 50% were calculated. Synergy was analysed according to Chou and Talalay method. In-vivo toxicity was evaluated for 14 days in rabbit vaginal mucosa. RESULTS: 5-Hydroxytyrosol inhibited HIV-1 infections of recombinant or wild-type viruses in all the target cells tested. Moreover, 5-hydroxytyrosol showed similar inhibitory concentration 50% values for infections with NRTIs, NNRTIs, protease inhibitors and INIs resistant viruses; founder viruses and all the subtypes tested. Combination of 5-hydroxytyrosol with tenofovir was found to be synergistic, whereas it was additive with lamivudine and emtricitabine. In-vivo toxicity of 5-hydroxytyrosol was very low even at the highest tested doses. CONCLUSION: 5-Hydroxytyrosol displayed a broad anti-HIV-1 activity in different cells systems in the absent of in-vivo toxicity, therefore supporting its candidacy as a potential new class of microbicides.es_ES
dc.description.sponsorshipAIM-HIV Network of Excellence of the EU, grant number HEALTH-F3-2012-305938. CHAARM European Community's Seventh Framework programme (FP7/2007-2013) under grant agreement no. 242135. Instituto de Salud Carlos III (Intrasalud PI12/0056). The following reagents were obtained through the NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: tenofovir, lamivudine, emtricitabine, nevirapine and raltegravir.es_ES
dc.language.isoenges_ES
dc.publisherLippincott Williams & Wilkins (LWW) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.meshAnimalses_ES
dc.subject.meshAnti-Infective Agentses_ES
dc.subject.meshCells, Culturedes_ES
dc.subject.meshDrug Synergismes_ES
dc.subject.meshFemalees_ES
dc.subject.meshHIV-1es_ES
dc.subject.meshHuman Activitieses_ES
dc.subject.meshHumanses_ES
dc.subject.meshLeukocytes, Mononucleares_ES
dc.subject.meshMicrobial Sensitivity Testses_ES
dc.subject.meshPhenylethyl Alcoholes_ES
dc.subject.meshRabbitses_ES
dc.titleHydroxytyrosol: a new class of microbicide displaying broad anti-HIV-1 activityes_ES
dc.typeresearch articlees_ES
dc.rights.licenseAtribución-NoComercial-SinObraDerivada 4.0 Internacional*
dc.identifier.pubmedID27677167es_ES
dc.format.volume30es_ES
dc.format.number18es_ES
dc.format.page2767-2776es_ES
dc.identifier.doi10.1097/QAD.0000000000001283es_ES
dc.contributor.funderUnión Europea. Comisión Europea. 7 Programa Marco 
dc.contributor.funderInstituto de Salud Carlos III 
dc.description.peerreviewedes_ES
dc.identifier.e-issn1473-5571es_ES
dc.relation.publisherversionhttps://doi.org/10.1097/QAD.0000000000001283es_ES
dc.identifier.journalAIDS (London, England)es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/HEALTH-F3-2012-305938es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/FP7/2007-2013es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/242135es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PI12/0056es_ES
dc.rights.accessRightsopen accesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinObraDerivada 4.0 Internacional
This item is licensed under a: Atribución-NoComercial-SinObraDerivada 4.0 Internacional